Léčba chronické myeloidní leukemie na severní Moravě: výsledky z období 1990 až 2005.

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F07%3A00004381" target="_blank" >RIV/61989592:15110/07:00004381 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Treatment of chronic myeloid leukemia in Northern Moravia: results during the perion 1990-2005

Popis výsledku v původním jazyce

We report the results opf conservative treatment of CML in Northern Moravia in 1990-2005. 38 (36%) of 107 patients (pts) treated with interferon (INF) achieved major or better cytogenetic response (CR). OS of pts treated with INF (median 99 months) was influenced by Sokal score and achievement of CR (p=0.0031 and 0.0063). Only 9 (8%) pts are continuing in INF at present. Nearly half of the pts has stopped INF due to the primary resistance. Secondary resistance and intolerance were the cause in 27% and 13% of pts, respectively. 6 pts have stopped the therapy after achievement of molecular response continuing without treatment 9 to 71 months. Treatment with imatinib (IM) was evaluated in 102 pts. 86 pts have started IM in chronic phase, 14 in acceleration and 2 in blastic phase. Interval from diagnosis to initiation of IM ranged from 1 to 135 months (me 9). 28 pts were treated with IM early after diagnosis, 4 were pretreated with oral chemotherapy and 70 pts with INF. IM was indicated du

Název v anglickém jazyce

Treatment of chronic myeloid leukemia in Northern Moravia: results during the perion 1990-2005

Popis výsledku anglicky

We report the results opf conservative treatment of CML in Northern Moravia in 1990-2005. 38 (36%) of 107 patients (pts) treated with interferon (INF) achieved major or better cytogenetic response (CR). OS of pts treated with INF (median 99 months) was influenced by Sokal score and achievement of CR (p=0.0031 and 0.0063). Only 9 (8%) pts are continuing in INF at present. Nearly half of the pts has stopped INF due to the primary resistance. Secondary resistance and intolerance were the cause in 27% and 13% of pts, respectively. 6 pts have stopped the therapy after achievement of molecular response continuing without treatment 9 to 71 months. Treatment with imatinib (IM) was evaluated in 102 pts. 86 pts have started IM in chronic phase, 14 in acceleration and 2 in blastic phase. Interval from diagnosis to initiation of IM ranged from 1 to 135 months (me 9). 28 pts were treated with IM early after diagnosis, 4 were pretreated with oral chemotherapy and 70 pts with INF. IM was indicated du

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2007

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Blood reviews

ISSN

0268-960X

e-ISSN

—

Svazek periodika

21

Číslo periodika v rámci svazku

Suppl. 1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

79

Strana od-do

79

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—